MA46995A - Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase - Google Patents

Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase

Info

Publication number
MA46995A
MA46995A MA046995A MA46995A MA46995A MA 46995 A MA46995 A MA 46995A MA 046995 A MA046995 A MA 046995A MA 46995 A MA46995 A MA 46995A MA 46995 A MA46995 A MA 46995A
Authority
MA
Morocco
Prior art keywords
lymphocytes
therapeutic
compositions
methods
combination
Prior art date
Application number
MA046995A
Other languages
English (en)
Inventor
Oleksandr Baturevych
Michael Ports
Jim Qin
Ruth Salmon
Original Assignee
Acerta Pharma Bv
Acerta Pharma Llc
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerta Pharma Bv, Acerta Pharma Llc, Juno Therapeutics Inc filed Critical Acerta Pharma Bv
Publication of MA46995A publication Critical patent/MA46995A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA046995A 2016-12-03 2017-12-01 Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase MA46995A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662429732P 2016-12-03 2016-12-03
US201762581644P 2017-11-03 2017-11-03

Publications (1)

Publication Number Publication Date
MA46995A true MA46995A (fr) 2019-10-09

Family

ID=60955391

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046995A MA46995A (fr) 2016-12-03 2017-12-01 Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase

Country Status (9)

Country Link
US (2) US11590167B2 (fr)
EP (1) EP3548046A2 (fr)
JP (2) JP2020511462A (fr)
CN (1) CN110545826A (fr)
AU (1) AU2017368331A1 (fr)
CA (1) CA3045339A1 (fr)
MA (1) MA46995A (fr)
MX (2) MX2019006288A (fr)
WO (1) WO2018102785A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019532997A (ja) * 2016-11-03 2019-11-14 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法とｂｔｋ阻害剤との併用療法
CN118948892A (zh) * 2017-05-01 2024-11-15 朱诺治疗学股份有限公司 细胞疗法与免疫调节化合物的组合
KR20200003913A (ko) * 2017-05-10 2020-01-10 이오반스 바이오테라퓨틱스, 인크. 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
CN109136276A (zh) * 2018-09-30 2019-01-04 北京鼎成肽源生物技术有限公司 一种rfft2细胞的构建方法
CA3117978A1 (fr) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Procedes et combinaisons pour le traitement et la modulation de lymphocytes t
WO2020180733A1 (fr) * 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion de lymphocytes infiltrant les tumeurs à partir de tumeurs liquides et leurs utilisations thérapeutiques
WO2021009510A1 (fr) * 2019-07-16 2021-01-21 Autolus Limited Procédé de préconditionnement d'un sujet qui est sur le point de recevoir une thérapie par lymphocytes t
JP2022554348A (ja) 2019-11-05 2022-12-28 ジュノー セラピューティクス インコーポレイテッド 治療用ｔ細胞組成物の属性を決定する方法
JP2023520916A (ja) * 2020-04-08 2023-05-22 リミックス セラピューティクス インコーポレイテッド スプライシングを調整するための化合物及び方法
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
US20240173353A1 (en) * 2021-03-16 2024-05-30 Shanghai Iaso Biotechnology Co., Ltd. Universal chimeric antigen receptor t-cell and application thereof
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
WO2026020055A2 (fr) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Procédés d'évaluation d'exosomes dans une composition cellulaire et utilisations associées

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (fr) 1994-10-26 1996-05-09 Procept, Inc. Recepteurs de lymphocites t monocatenaires solubles
WO1996018105A1 (fr) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Recepteur de lymphocyte t monocatenaire
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (fr) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple
ATE533784T1 (de) 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
WO1999060120A2 (fr) 1998-05-19 1999-11-25 Avidex Limited Recepteur de lymphocyte t soluble
EP1109921A4 (fr) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CA2501870C (fr) 2002-10-09 2013-07-02 Avidex Limited Recepteurs de lymphocytes t de recombinaison a chaine unique
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
UA83509C2 (en) 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
US8101770B2 (en) 2004-12-16 2012-01-24 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
GB0624689D0 (en) 2006-12-11 2007-01-17 Glaxo Group Ltd Novel fluorescent kinase ligands and methods employing the same
SG10202107066WA (en) 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
TWI552752B (zh) 2007-10-19 2016-10-11 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
WO2009124119A2 (fr) 2008-04-01 2009-10-08 The Trustes of Columbia University in the City of New York Inhibiteurs de phosphodiestérase et utilisations de ceux-ci
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
CA2730930C (fr) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibiteurs de tyrosine kinase de bruton pour le traitement de tumeurs solides
EP2331566B1 (fr) 2008-08-26 2015-10-07 City of Hope Procédé et compositions pour fonctionnement amélioré d'effecteur antitumoral de lymphocytes t
PL2918604T3 (pl) 2008-11-07 2018-05-30 Amgen Research (Munich) Gmbh Leczenie pediatrycznej ostrej białaczki limfoblastycznej
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
NZ598985A (en) 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
EP2486049A1 (fr) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Récepteurs de lymphocytes t à chaîne unique humains
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
CA3007787C (fr) 2010-06-03 2020-03-10 Pharmacyclics Llc Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
MX342164B (es) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
MX336875B (es) 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013026837A1 (fr) 2011-08-23 2013-02-28 Roche Glycart Ag Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t.
CN103073508B (zh) 2011-10-25 2016-06-01 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP2773639B1 (fr) 2011-11-03 2017-04-26 F. Hoffmann-La Roche AG Piperazines alkyles comme inhibiteurs de l'activite btk
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
US9199997B2 (en) 2011-11-29 2015-12-01 Ono Pharmaceutical Co., Ltd. Purinone derivative hydrochloride
KR20130076046A (ko) 2011-12-28 2013-07-08 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
CN104080789B (zh) 2012-01-31 2016-05-11 南京奥昭生物科技有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
CA2861491C (fr) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Recepteurs d'antigene chimeres bispecifiques et utilisations therapeutiques de ceux-ci
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
EP2844743B1 (fr) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Récepteurs de lymphocyte t à affinité augmentée et procédés pour fabriquer ceux-ci
US9662343B2 (en) * 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
HRP20230297T1 (hr) 2012-07-13 2023-05-12 The Trustees Of The University Of Pennsylvania UPRAVLJANJE TOKSIČNOŠĆU ZA ANTI-TUMORSKO DJELOVANJE CAR-a
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
RU2658485C2 (ru) 2012-10-24 2018-06-21 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы м971
KR101668574B1 (ko) 2012-11-02 2016-10-24 화이자 인코포레이티드 브루톤 티로신 키나제 억제제
TW201427664A (zh) 2012-11-02 2014-07-16 Pharmacyclics Inc Ｔｅｃ家族激酶抑制劑佐劑療法
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
DK2940014T3 (en) 2012-12-28 2018-12-10 Crystalgenomics Inc 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
EP2970985A1 (fr) 2013-03-14 2016-01-20 Fred Hutchinson Cancer Research Center Compositions et méthodes de modification de cellules à des fins thérapeutiques
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CN104177338B (zh) 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
TWI648272B (zh) 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 經取代之四氫咔唑及咔唑甲醯胺化合物
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
BR112016006978A2 (pt) 2013-09-30 2017-08-01 Pharmacyclics Llc inibidores de tirosina quinase de bruton
WO2015057992A1 (fr) 2013-10-16 2015-04-23 Izumi Raquel Inhibiteurs btk pour la mobilisation hématopoïétique
WO2015084892A1 (fr) 2013-12-02 2015-06-11 Cornell University Méthodes de traitement des troubles de prolifération des lymphocytes b
US9931347B2 (en) 2013-12-03 2018-04-03 Iomet Pharma Ltd. Pharmaceutical compound
CN105979948A (zh) 2013-12-05 2016-09-28 安塞塔制药公司 Pi3k抑制剂和btk抑制剂的治疗组合
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
US20170335281A1 (en) * 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
WO2015146159A1 (fr) 2014-03-25 2015-10-01 Ono Pharmaceutical Co., Ltd. Agent prophylactique et/ou agent thérapeutique pour lymphome diffus à grandes cellules b
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN105085474B (zh) 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
CN104829610B (zh) 2014-06-20 2017-03-15 中国科学院合肥物质科学研究院 一种新型布鲁顿酪氨酸激酶抑制剂
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
TW201618783A (zh) * 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
PL3179991T3 (pl) 2014-08-11 2022-02-14 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
CN105884747B (zh) 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
CN105399756B (zh) 2014-09-05 2019-06-25 广东东阳光药业有限公司 Btk抑制剂及其用途
CN105153154A (zh) 2014-09-26 2015-12-16 广东东阳光药业有限公司 Btk抑制剂及其用途
CN105837576B (zh) 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
US9278919B1 (en) 2015-03-13 2016-03-08 Yong Xu Synthesis of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
CN104844573A (zh) 2015-04-17 2015-08-19 中国药科大学 嘧啶类btk抑制剂、其制备方法及医药用途
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
EP3747472B1 (fr) 2015-09-15 2024-04-03 Acerta Pharma B.V. Combinaisons thérapeutiques d'un inhibiteur cd19 et d'un inhibiteur btk
TWI755547B (zh) 2016-01-21 2022-02-21 美商輝瑞股份有限公司 靶向表皮生長因子受體變異體iii之嵌合型抗原受體
CN105732638B (zh) 2016-01-22 2018-01-30 成都倍特药业有限公司 一种具有螺环或桥环结构的布鲁顿酪氨酸激酶抑制剂及其制备方法
WO2017210617A2 (fr) 2016-06-02 2017-12-07 Porter, David, L. Régimes thérapeutiques pour cellules exprimant un récepteur antigénique chimérique (car)
CA3024725A1 (fr) 2016-06-06 2017-12-14 Juno Therapeutics, Inc. Procedes de traitement de malignites de lymphocytes b au moyen d'une therapie cellulaire adoptive
DK3523326T3 (da) 2016-10-04 2020-08-03 Prec Biosciences Inc Samstimulerende domæner til anvendelse i genetisk modificerede celler
JP2019532997A (ja) 2016-11-03 2019-11-14 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法とｂｔｋ阻害剤との併用療法
BR112019017767A2 (pt) 2017-02-27 2020-04-07 Juno Therapeutics Inc composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
EP3621988A1 (fr) 2017-05-09 2020-03-18 Bellicum Pharmaceuticals, Inc. Procédés pour augmenter ou modifier la transduction de signal
IL315340A (en) 2017-09-01 2024-10-01 Lonza Walkersville Inc End-to-end cell therapy automation
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
MA51210A (fr) 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
KR20210044736A (ko) 2018-05-03 2021-04-23 주노 쎄러퓨티크스 인코퍼레이티드 키메라 항원 수용체(ｃａｒ) ｔ세포 요법과 키나제 억제제의 조합요법
EP3801769A1 (fr) 2018-05-25 2021-04-14 Novartis AG Polythérapie comprenant des thérapies par récepteur antigénique chimérique (car)
US20210223248A1 (en) 2018-06-01 2021-07-22 Fred Hutchinson Cancer Research Center Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods
CN113692285A (zh) 2018-11-30 2021-11-23 朱诺治疗学股份有限公司 在过继细胞疗法中给药和治疗b细胞恶性肿瘤的方法
IL292665B2 (en) 2019-11-06 2026-02-01 Kite Pharma Inc Chimeric antigen receptor T cell therapy

Also Published As

Publication number Publication date
WO2018102785A2 (fr) 2018-06-07
US20240016840A1 (en) 2024-01-18
US11590167B2 (en) 2023-02-28
WO2018102785A3 (fr) 2018-07-26
MX2019006288A (es) 2020-10-01
CA3045339A1 (fr) 2018-06-07
JP2023036841A (ja) 2023-03-14
AU2017368331A1 (en) 2019-06-13
US20190328786A1 (en) 2019-10-31
EP3548046A2 (fr) 2019-10-09
CN110545826A (zh) 2019-12-06
JP2020511462A (ja) 2020-04-16
MX2024002021A (es) 2024-03-06

Similar Documents

Publication Publication Date Title
MA46995A (fr) Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
EP3701041A4 (fr) Méthodes et compositions pour traiter des maladies associées à des lymphocytes t épuisés
EP3612181A4 (fr) Thérapies d'association avec des inhibiteurs d'ehmt2
EP3325520A4 (fr) Formulations polymères pour l'utilisation avec des milieux électro-optiques
EP3402549A4 (fr) Compositions pour micro-aiguilles et méthodes d'utilisation de celles-ci
EP3679141C0 (fr) Méthodes et compositions pour inhiber l'expression de la ldha
EP3353309A4 (fr) Compositions et méthodes pour l'édition génomique
EP3429591A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
EP3402483A4 (fr) Procédés et compositions pour l'activation de lymphocytes t gamma-delta
MA43515A (fr) Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
EP3335471A4 (fr) Radiomessagerie pour un équipement d'utilisateur de faible complexité et/ou un équipement d'utilisateur en mode d'amélioration de couverture
SI3352584T1 (sl) Sestavki in postopki za sintezo 5'-omejenih RNAjev
EP3635100A4 (fr) Compositions et procédés pour exprimer l'otoferline
MA51074A (fr) Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
EP3430057A4 (fr) Utilisation d'inhibiteurs d'ape1/ref-1 dans des polythérapies pour le traitement du cancer
EP3310343A4 (fr) Compositions implantables pour administration de médicaments et méthodes d'utilisation desdites compositions
EP3040355A4 (fr) Modificateur d'asphalte et composition d'asphalte le contenant
EP3331960A4 (fr) Agents d'inversion non ioniques pour latex eau-dans-huile et procédés d'utilisation
IL280827A (en) Integrin alpha 4 antagonists and compositions comprising same for use in treating ocular conditions
EP3302588A4 (fr) Compositions et méthodes pour l'adhérence à des surfaces
EP3651764A4 (fr) Composés rétinoïdes et rexinoïdes immunomodulateurs en combinaison avec des modulateurs immunitaires pour l'immunothérapie du cancer
FR3016768B1 (fr) Utilisation d'une composition enzymatique dans l'alimentation des ruminants
EP3377069A4 (fr) Composition de phéromone pour stimuler la reproduction chez des femelles suidés et procédés d'utilisation
EP3512517A4 (fr) Utilisation de pridopidine pour le traitement de l'anxiété et de la dépression
EP3432886A4 (fr) Inhibiteurs de kinase pim en combinaison avec des modulateurs/inhibiteurs d'épissage d'arn pour le traitement de cancers